MedTrace Logo

Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)

NCT00934466 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2015-06-24

No results posted yet for this study

Summary

This study will assess transcranial magnetic stimulation (TMS) as a biomarker and characterize TMS readouts of the activity of MK2637 and dextromethorphan. Resting quantitative electroencephalography(qEEG) readouts are also characterized with MK2637 and dextromethorphan.

Conditions

Interventions

DRUG

MK2637

Single dose of 120 mg MK2637 capsules in one of five treatment periods.

DRUG

Comparator: MK2637

Single dose of 50 mg MK2637 capsules in one of five treatment periods.

DRUG

Comparator: Placebo

Single dose of placebo only in one of five treatment periods.

DRUG

Comparator: Dextromethorphan

Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.

DRUG

Comparator: Dextromethorphan

Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-12-31
Completion
2009-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00934466 on ClinicalTrials.gov